Introduction {#sec1-1}
============

Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal tract, characterized by uncontrolled immune responses and severe intestinal inflammation. Ulcerative colitis (UC) and Crohn\'s disease (CD) are two major subtypes of IBD that have distinct clinical and histopathological characteristics.\[[@ref1][@ref2]\] Although the exact etiology of IBD is still unknown, genetic and environmental factors are believed to have important roles in disease predisposition and pathogenesis.\[[@ref3][@ref4]\] Epidemiological data have revealed that no single gene or distinct mechanism can explain all the aspects of IBD and genetic predisposition to UC and CD depends on the contribution of several candidate genes, such as IL23R, IL12B, NKX2-3, XRCC1, CARD15, and HLA. Genetic factors seem to be more involved in the pathogenesis and clinical course of CD than UC.\[[@ref5][@ref6][@ref7][@ref8][@ref9]\]

Highly reactive molecules, such as reactive oxygen species (ROS) and imbalanced immune responses are known to be one of the major risk factors of intestinal inflammation.\[[@ref10][@ref11]\] ROS might be products of bacterial fermentation and endogenous metabolism of xenobiotics within the intestinal lumen. They might also be produced by activated immune cells.\[[@ref12][@ref13][@ref14]\] Biotransformation enzymes such as glutathione S-transferases (GSTs), epoxide hydrolases and cytochrome P450s play a key role in the metabolism of ROS and xenobiotics. Allelic polymorphism in genes encoding these enzymes could change their activities, resulting in defective detoxification and finally, might confer susceptibility to inflammatory diseases or even cancers.\[[@ref12][@ref15][@ref16][@ref17]\]

GSTs are a family of multi-functional enzymes having detoxifying properties which catalyze the conjugation of mutagenic electrophiles and peroxidized lipids with nucleophilic glutathione, yielding hydrophilic, and less toxic metabolites.\[[@ref2][@ref18]\] GSTs consist of three major families: Cytosolic, microsomal, and mitochondrial. Human cytosolic GSTs are divided into eight classes (alpha, zeta, theta, mu, pi, sigma, kappa, and omega) of which mu (GSTM), theta (GSTT), pi (GSTP), and alpha (GSTA) families display significant gene polymorphisms.\[[@ref19][@ref20]\] An important genetic polymorphism in GSTM1 coding gene, located on chromosome 1p13.3, has been described as partial gene deletion (GSTM1 null genotype) leading to complete absence of enzyme activity. A deletion polymorphism was also reported for GSTT1 gene, located on chromosome 22q11.2 (GSTT1 null genotype).\[[@ref9][@ref17]\] As recently reviewed, the prevalence of GSTM1 null allele ranges from 22% in Africans to 62% among Europeans, whereas GSTT1 null status differs from 20% to 60% in Caucasian and Asian people, respectively.\[[@ref21][@ref22]\] Due to the important role of GSTs in oxidative stress and detoxifying carcinogens, GSTM1 and GSTT1 allelic polymorphisms may result in less effective removal of intestinal toxic metabolites, thus modifying the susceptibility to UC and CD.\[[@ref2][@ref14][@ref22][@ref23]\]

This study aimed to evaluate the frequency of GSTM1 and GSTT1 genetic polymorphisms in IBD patients and normal controls to explore the association between GSTs genotypes and prevalence of UC and CD in the south of Iran. This is the first report describing the GSTs gene polymorphism in the Iranian IBD patients.

Materials and Methods {#sec1-2}
=====================

Patients and controls population {#sec2-1}
--------------------------------

A total of 106 consecutive patients with IBD (94 with UC and 12 with CD) consulting the IBD registry center of the Motahari Clinic, affiliated by the Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, were included in this study. Case--control study was performed on subjects recruited between 2011 and 2013. The diagnosis of IBD was confirmed by gastroenterology attending, based on clinical, endoscopic, and histological findings in accordance with Lennard-Jones criteria. Patients without pathologic proof were not included. A total of 243 age- and sex-matched healthy controls were selected from healthy blood donors referred to the National Blood Transfusion Organization, Shiraz, Iran. Informed consent was obtained from all participants for being included in the study. All procedures followed were in accordance with the ethical standards of the Shiraz University of Medical Sciences committee on human experimentation and with the Helsinki declaration of 1975, as revised in 2008.

DNA extraction {#sec2-2}
--------------

Two milliliters of venous blood samples were obtained from each IBD patient and also from controls and stored in vacuum tubes containing EDTA at −20°C before examination. Genomic DNA was extracted from the peripheral blood leukocytes using Accuprep Genomic DNA Extraction Kit (Bioneer, Korea) according to the manufacturer\'s instructions.

Genotyping of glutathione S-transferases genes polymorphisms {#sec2-3}
------------------------------------------------------------

Genetic polymorphisms in GSTM1 (rs 366631) and GSTT1 (rs 17856199) genes were determined using multiplex polymerase chain reaction (PCR) followed by gel electrophoresis. The PCR reactions were performed in a final volume of 25 μl, containing 100 ng genomic DNA, 30 pmol of each primers, 0.3 mM dNTP, 1.5 mM MgCl2 and 1.5 U Taq DNA polymerase (Fermentas). The appropriate fragments of the GSTM1 and GSTT1 genes were amplified using the following specific primers: GSTM1 forward primer, 5'-GAACTCCCTGAAAAGCTAAAGC-3' and reverse primer 5'-GTTGGGCTCAAATATACGGTGG-3'; GSTT1 forward primer, 5'-TTCCTTA CTGGTCCTCACATCTC-3' and reverse primer 5'-TCACCGGATCATGGCCAGCA-3'.\[[@ref2]\] Beta-globin gene amplification was also used as an internal control in the multiplex PCR, for which the primers were as follows: Forward primer 5′-CAACTTCATCCACGTTCACC-3′ and reverse primer 5′-GAAGAGCCAAGGACAGGTAC-3′.

The amplification conditions consisted of an initial denaturation at 95°C for 5 min, followed by 35 cycles at 94°C for 1 min, 64.5°C for 1 min and 72°C for 1 min, with a final extension at 72°C for 5 min. PCR products were separated by electrophoresis on 2% agarose gel and visualized by UV illumination using ethidium bromide staining \[[Figure 1](#F1){ref-type="fig"}\].

![Polymerase chain reaction amplification of the GSTM1, GSTT1 and internal control beta-globin genes, separated by electrophoresis on 2% agarose gel. Lane 5 shows GSTM1 (+)/GSTT1 (+) sample, Lanes 1 and 3 contain GSTM1 (+)/GSTT1 (null) samples, Lane 2 GSTM1 (null)/GSTT1 (+) and Lane 4 shows GSTM1 (−)/GSTT1 (−) sample](ABR-6-67-g001){#F1}

Statistical analysis {#sec2-4}
--------------------

Statistical significant differences in the distribution of polymorphisms between groups were analyzed using Chi-square test. Odds ratios with 95% confidence intervals (95% CI) were also calculated. In all analyses, a two-tailed *P* \< 0.05 was considered statistically significant. All statistical analyses were conducted using SPSS software, version 18 (SPSS Inc., Chicago, IL, USA).

Results {#sec1-3}
=======

The average age was 36.6 ± 12.9 years in UC patients and 35 ± 13.3 in CD patients. The patients' and controls' demographic characteristics are presented in [Table 1](#T1){ref-type="table"}. Genotypes of GSTM1 and GSTT1 were screened at the genome level by PCR. The PCR products of GSTM1 (215 bp) and GSTT1 (480 bp) were detected in normal samples but absent in individuals who carry only the null allele \[[Figure 1](#F1){ref-type="fig"}\]. The frequencies for GSTM1 and GSTT1 deletion polymorphisms were compared between IBD patients and control group. The genotype frequencies were also compared between UC and CD patients with the control group, separately. There was a significantly higher rate of GSTM1 null genotype in IBD (including both UC and CD) patients compared to controls (61.32% vs. 47.32%, *P* = 0.01, OR = 1.76, 95% CI = 1.10--2.80) \[[Table 2](#T2){ref-type="table"}\].
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Demographic characteristics of inflammatory bowel diseases patients and healthy controls

![](ABR-6-67-g002)

###### 

Frequency distribution of GSTM1 gene polymorphisms (rs 366631) in inflammatory bowel diseases patients and healthy controls

![](ABR-6-67-g003)

In UC patients, a significantly higher frequency of GSTM1 null genotype was observed compared to healthy controls (59.57% vs. 47.32%. *P* =0.045, OR = 1.64, 95% CI = 1.01--2.65). On the contrary, no significant difference was observed between control and patient groups regarding GSTT1 gene polymorphism (27.98% vs. 20.21%. *P* = 0.146, OR = 0.65, 95% CI = 0.36--1.16) \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Frequency distribution of GSTT1 gene polymorphisms (rs 17856199) in inflammatory bowel diseases patients and healthy controls

![](ABR-6-67-g004)

In CD patients, no significant differences in the frequency of GSTM1 and GSTT1 null genotypes were observed between patient and control groups (75% vs. 47.32%, *P* = 0.076, OR = 3.33, %95 CI = 0.88--12.63 and 16.66% vs. 27.98%, *P* = 0.399, OR = 0.51, %95 CI = 0.11--2.41, respectively) \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

Discussion {#sec1-4}
==========

ROS and xenobiotics are of the most important factors affecting inflammation and tissue injuries in the mucosa. Imbalance between production and detoxification of these toxic compounds may play an important role in the etiology of intestinal inflammatory diseases.\[[@ref24][@ref25]\] Antioxidant defenses have an important role in the metabolism and removal of toxic molecules and polymorphism in the genes related to their activities could increase the susceptibility to several diseases, especially cancers.\[[@ref12][@ref16][@ref22]\]

GSTs are detoxifying enzymes with high expression in the liver, gonads and colon.\[[@ref2][@ref26]\] GSTM1 and GSTT1 are two GSTs main subclasses in human involved in the metabolism of different toxins such as polycyclic aromatic hydrocarbons, epoxides, methane, and ethylene oxide.\[[@ref2]\] Deletion polymorphism in GSTM1 and GSTT1 genes could result in nonfunctional (null) alleles and loss of enzymatic activities. It has been shown that individuals carrying the GSTM1 and GSTT1 null genotypes may have an impaired detoxifying ability and, therefore, be at increased risk of different cancers, including lung,\[[@ref27][@ref28]\] breast,\[[@ref29]\] bladder\[[@ref30]\] and colorectal cancers.\[[@ref19][@ref21]\] A significant association between GSTM1 and GSTT1 gene polymorphisms and greater susceptibility to UC and CD were also reported for different ethnic groups.\[[@ref2][@ref14][@ref22]\]

In the present research, we studied the GSTM1 and GSTT1 deletion polymorphisms in Iranian UC and CD patients as well as healthy controls. The prevalence of GSTM1 and GSTT1 null genotypes in controls (47.32% and 27.98%, respectively) were similar to previously reported results.\[[@ref12][@ref14][@ref22]\] Our finding showed a significantly higher frequency of GSTM1 null genotype in all IBD (*P* = 0.01) and also in UC subgroup (*P* = 0.045) patients relative to controls, but not in the CD patients (*P* = 0.076). However, no significant differences were observed between the frequency of GSTT1 null genotype in the IBD patients (*P* = 0.10), UC (*P* = 0.146) and CD (*P* = 0.399) subgroups, compared to the controls. The observed higher frequency of the GSTM1 null genotype in IBD and UC Iranian patients relative to the controls is in consistent with previous studies had done on Asian populations. These studies have shown an important role of GSTM1 gene deletion in the development of UC.\[[@ref2][@ref14][@ref23]\] Ye *et al*. reported a positive association of GSTM1 and GSTT1 null alleles with susceptibility to UC in central China population and suggested a predominant role of GSTM1 to influence the UC.\[[@ref2]\] An association between the null genotype of GSTM1 with UC (but not CD) was also reported in Indian IBD patients.\[[@ref23]\] Conversely, an Israeli study found a lower GSTM1 null frequency in IBD and CD Arab Moslem patients than controls.\[[@ref22]\]

The GSTT1 null genotype has been correlated with the increased risk of UC and CD in different populations,\[[@ref2][@ref14][@ref22][@ref23]\] however in some studies such a relationship was not found.\[[@ref12][@ref13][@ref31]\] In our study, the GSTT1 null frequencies did not differ significantly between the UC and CD patients compared to controls. This is in agreement with the results of de Jong *et al* and Ernst *et al*., who showed no association between GSTT1 gene deletion and occurrence of UC and CD in the Netherlands and Danish population, respectively.\[[@ref12][@ref31]\] Overall, it could be concluded that GSTM1 and GSTT1 null alleles may confer more susceptibility to intestinal inflammatory disorders, although these conflicting results may be due to confounding variables, such as ethnicity, different genetic background and additional susceptibility genes.

Our results indicate that absence of the GSTM1 and GSTT1 functional genes does not play an important role in the pathophysiology of CD in Iranian population. However, it should be noted that making a conclusion based on the results obtained from a small CD patients group (*n* = 12) might not be very exact (the limitation of this study). More comprehensive studies regarding larger sample sizes are needed for the more definite conclusion.

Conclusion {#sec1-5}
==========

A significant association was found between the GSTM1 null genotype and greater susceptibility to IBDs and UC in the Iranian population. These results suggest that GSTM1 gene polymorphism could be considered as a possible genetic predisposing factor for IBD and UC in Iranian population.
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